Spectrum has received approval to market Levoleucovorin ([6S]-leucovorin injection), the pharmacologically active enantiomer of leucovorin. Levoleucovorin is indicated after high-dose methotrexate therapy in patients with osteosarcoma, and to diminish the toxicity and counteract the effects of impaired methotrexate elimination or inadvertent overdose of folic acid antagonists. Levoleucovorin, a folate analog, will be supplied in 50mg vials of freeze-dried powder and is expected to be available in June 2008.

For more information call (949) 788-6700 or visit www.spectrumpharm.com.